 | Indian pharmaceutical companies are grabbing headlines on an almost daily basis and are increasingly carving out market shares for themselves in the US and many other markets around the world. Several leading Indian pharmaceutical companies have applied themselves to the challenge of entering Western markets with great success. These companies now present a very serious threat to the existing Western generic companies in their domestic markets as they take ever-larger market shares and increase the levels of competition. |
|
| One in five people suffer from moderate to severe chronic pain, and one in three is unable or less able to maintain an independent lifestyle due to their pain. Between 50 and 60 percent of people with chronic pain are less able or unable to exercise, sleep normally, perform household chores, attend social activities, drive a car, or walk.The value of the pharmaceutical market for pain relief in 2007 reflects this seeming worldwide epidemic of pain. The Global Pain Therapeutics Market assesses key pain management therapeutics - such as opioids, triptans, anticonvulsants, Cox-II inhibitors and traditional NSAIDs and are discussed in terms of their past, present and future value and the role they are playing in the effective management of pain. This report discusses the key products within each of these areas and outlines the drivers of these markets as well as the restraints on them. |
|
| The global anti-infective market is currently valued at US$66.5 billion with antibacterial agents accounting for over 50% of sales. The antibacterial market is set to grow to over US$45.0 billion by 2012, driven by the uptake of newer antibacterial agents such as glycopeptides and carbapenems which demonstrate resistance to methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) as well as other emerging strains. |
|
| The global anti-infective market is currently valued at US$66.5 billion with antiviral agents accounting for 24% of sales (excluding vaccines which target viral infectious diseases).According to Arrowhead Publishers’ new report The Antivirals Market: R&D Pipelines, Markey Analysis and Competitive Landscape, the anti-viral market is set to grow to over US$25.0 billion by 2012 driven by the uptake of newer anti-retroviral agents in combination therapy and the launch of ten new products for the treatment of HIV and hepatitis which will address the need of treatment-resistant patients. This will help to stem the tide of this prevalent and often lethal killer in our society today. |
|
| Offshoring clinical trials to emerging markets around the world is receiving increasing attention as a very attractive alternative in the clinical development process. This follows as a natural reaction to already successful offshoring activities in the IT industry. The big question is: Do clinical research capabilities comparable to the US in terms of sophistication and FDA-compliance exist anywhere else in the world? And if they do, are they ready to handle the huge surge in business likely headed their way? |
|
| The clinical trials industry has clear potential for strong growth in the future, driven by technological and scientific advances. This trend is complemented by the development of new trial designs, with a view to rationalizing and accelerating the drug discovery process by identifying failures at an earlier stage. |
|
| With a market size of US$14.5 billion in 2005 and an anticipated value of US$16.5 billion in 2006, the neurodegenerative market represents a valuable, fast-growing opportunity in the pharma/biotech industry. An increase in the number of aged people, increased life expectancy, unmet clinical needs together with advances in treatments of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease will continue to contribute to the expansion of the global market. |
|
| In 2005, the antibodies market was valued at an estimated US$14 billion, accounting for over 24 percent of the total protein therapeutics market. This share increased substantially since 2001, when it barely surpassed 13 percent. Monoclonal antibody (MAbs) therapies have been posting the fastest growth within the protein therapeutics market. According to Arrowhead Publishers’ report Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline Insight the value of this market is set to reach more than $16 billion in 2006This growth will continue in the coming years, boosted by a number of new MAbs on the market, new indications for successful medications, and their ability to treat conditions and diseases for which there is great unmet need. |
|
| The global protein therapeutics market was valued at US$57 billion in 2005. Biotechnology has made notable inroads in the field of protein therapeutics, resulting in some of the key products presently available in the category. Recombinant proteins are potentially advantageous in terms of higher efficacy and fewer side effects than other pharmaceutical products, as they can be more specifically targeted to the cause of the disease, rather than the treatment of its symptoms. |
|
| As competition in the pharmaceutical marketplace grows, companies are increasingly looking towards the drug delivery industry to maximize revenues and combat generic competitors. The search for more efficient drug delivery systems is also being driven by the rise in patient demand, healthcare and pharma cost containment, as much as by medical and technological advances. |
|
| The market for rheumatoid arthritis therapeutics has experienced remarkably strong growth during the past five years due to the introduction of the biological response modifiers (BRMs) to treatment regimens. The value of this market will reach nearly $13 billion by 2011. Sales of both Remicade and Enbrel continue to grow, while the introduction of Humira in 2003 has been a major stimulus to the market. All three of these products are now approved in both the US and Europe for rheumatoid arthritis. Added to this mix in 2006 was Rituxan and Orencia, which will both have an impact in the patient population unresponsive to other BRMs. As half-year 2006 revenues clearly indicate, revenues from the sales of all of these products will continue to trend positively in 2007. |
|
| Since the mid-1990s, pharma companies have devised their sales and marketing strategies based on Rx data. However, with the introduction of the AMA's Prescribing Data Restriction Program (PDRP) opt-out program in July 2006, pharma companies need to evaluate the impact of PDRP violation, mediate their PDRP compliance strategies, and revisit their existing Sales Force Effectiveness (SFE) practices. With the introduction of the PDRP, the use of physician Rx data by pharmaceutical companies will never be the same again. The PDRP prohibits access to physician-level Rx data, which directly impacts First Line Managers, Sales Representatives, and anyone else that accesses or distributes physician Rx data. |
|
| Diabetes is one of the largest therapeutic segments of global pharmaceutical sales and during the last 10 years it has grown by a compound average growth rate of nearly 20% from around US$4 billion in 1995 to over US$17 billion in 2005. Overall, anti-diabetic drugs sales are expected to grow dramatically over the next five years to over US$22 billion in 2012 as the addressable patient population continues to increase and new, oral, injectable and pulmonary premium priced products enter the market to address high unmet clinical needs.The Global Diabetes Market assesses the markets for diabetes therapeutics, as well as the markets for diagnostic products and those that treat diabetic complications. |
|
